Biomarin Pharmaceutical's Total Assets for the quarter that ended in Dec. 2023 was $6,842 Mil.
Warning Sign:
If a company builds assets at 10.6% a year, faster than its revenue growth rate of 7.5% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Biomarin Pharmaceutical's average Total Assets Growth Rate was 13.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 6.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 13.60% per year.
During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 65.40%. The lowest was -3.30%. And the median was 22.00%.
Total Assets is connected with ROA %. Biomarin Pharmaceutical's annualizedROA % for the quarter that ended in Dec. 2023 was 1.20%. Total Assets is also linked to Revenue through Asset Turnover. Biomarin Pharmaceutical's Asset Turnover for the quarter that ended in Dec. 2023 was 0.10.
Biomarin Pharmaceutical Total Assets Historical Data
The historical data trend for Biomarin Pharmaceutical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biomarin Pharmaceutical Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
4,690.04
5,848.02
6,004.77
6,375.07
6,841.60
Biomarin Pharmaceutical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
6,375.07
6,433.70
6,563.17
6,758.16
6,841.60
Biomarin Pharmaceutical Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Biomarin Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (NAS:BMRN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Biomarin Pharmaceutical's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Biomarin Pharmaceutical Total Assets Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 